Evidence map›Paper›PMID 32902688›Full record

ArticleMikrochimica acta2020

Hierarchical multifunctional graphene oxide cancer nanotheranostics agent for synchronous switchable fluorescence imaging and chemical therapy.

Yasaman Esmaeili, Ali Zarrabi, Seyede Zohreh Mirahmadi-Zare, Elham Bidram

Abstract read
PubMed Publisher
In one paragraph

Article in Mikrochimica acta, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 28 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 2 countries.

Yasaman EsmaeiliDepartment of Biotechnology, Faculty of Biological Science & Technology, University of Isfahan, Isfahan, Iran.
Ali ZarrabiDepartment of Biotechnology, Faculty of Biological Science & Technology, University of Isfahan, Isfahan, Iran. alizarrabi@sabanciuniv.edu.ORCID http://orcid.org/0000-0003-0391-1769
Seyede Zohreh Mirahmadi-ZareDepartment of Animal Biotechnology, Reproductive Biomedicine Research Center, Royan Institute for Biotechnology, ACECR, Isfahan, Iran. mirahmadi_zare@royaninstitute.org.
Elham BidramBiosensor Research Center (BRC), Department of Biomaterials, Nanotechnology, and Tissue Engineering, School of Advanced Technologies in Medicine, Isfahan University of Medical Sciences (IUMS), Isfahan, Iran.
Isfahan University of Medical Sciences · IRIsfahan University of Technology · IRRoyan Institute · IRSabancı Üniversitesi · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A nanotheranostics platform was synthesized based on PEGylated graphene oxide-gold nanoparticles and specified with aptamer toward the MUC-1-positive tumor cells. Subsequently, it was loaded with doxorubicin, used for non-invasive fluorescence imaging and therapy of breast and colon tumors. The success of the nano-coating at each synthesis step was characterized through FTIR, XRD, TGA, FE-SEM, EDAX, Zeta-potential, and fluorescence spectroscopy. Besides, the ability of the designed platform in targeted imaging, drug delivery, and in vitro therapy were evaluated using fluorescence microscopy and flow cytometry. The selected aptamer acts as a quencher, resulting in an "on/off" fluorescence biosensor. When the aptamer specifically binds to the MUC-1 receptor, its double strands separate, leading to the drug release and the recovery of the fluorescence of ("On" state) at the excitation wavelength of 300 nm. Based on cell toxicity results, this platform has more toxicity toward the MUC-1-positive tumor cells (HT-29 and MCF-7) compared  to MUC-1-negative cells (Hep-G2), representing its selective performance. Thus, this nano-platform can be introduced as a multifunctional cancer nanotheranostics system for tracing particular biomarkers, non-invasive imaging, and targeted chemotherapy. Graphical abstract.

Indexed as

GraphiteHumansMetal NanoparticlesNeoplasmsOptical Imaginggraphene oxideGraphiteAptamerCancer nanotheranosticsGraphene oxideNon-invasive imagingTargeted therapy

Identifiers

PMID32902688
OpenAlexW3086144727

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.